| Amal Therapeutics–VI Partners: investment, 201603 financing round Series A totalling CHF3m incl co-investor VI Partners |
2016-03-30 |
| BioChain–Epigenomics: molecular diagnostics, 201603– license excl blood-based lung cancer test for developm + commercialisation in China |
2016-03-30 |
| Zavante Therapeutics–SEVERAL: investment, 201603 financing round Series A $45m with $35m from new investors + $10m conversion of convertible notes |
2016-03-30 |
| Exiqon–Qiagen: investment, 201603–201606 conditional voluntary takeover offer DKK683m ($100m) |
2016-03-29 |
| Gadeta–SEVERAL: investment, 201603 financing round Series A €7m led by Medicxi Ventures + Baxalta Ventures with Utrecht Holdings + founders + managers |
2016-03-29 |
| ABBA Therapeutics–Ligand: transgenic animal technology, 201603– license to use OmniAb platform to develop MAbs + bi-specific ABs |
2016-03-28 |
| Bayer–Holta Invest: investment, 201603 existent Bayer listed as portfolio company of Holta Life Sciences |
2016-03-28 |
| Roche–Holta Invest: investment, 201603 existent Roche listed as portfolio company of Holta Life Sciences |
2016-03-28 |
| Diatron–Stratec: investment, 201603 acquisition 100% of Diatron MI PLC by Stratec from The Riverside Company |
2016-03-23 |
| Padlock Therapeutics–BMS: investment, 201603–201604 acquisition 100% for up to $600m |
2016-03-23 |
| Thuringia (govt)–High-Tech Gründerfonds: venture capital, 201603– collab renewed TSF + HTGF to jointly provide up to €3.15m for early financings |
2016-03-23 |
| Topas Therapeutics–EMBL: investment, 201603 financing round Series A totalling €14m incl co-investor EMBL Ventures |
2016-03-22 |
| Topas Therapeutics–Epidarex Capital: investment, 201603 financing round Series A totalling €14m led by Epidarex |
2016-03-22 |
| Topas Therapeutics–Evotec: investment, 201603 financing round Series A totalling €14m incl co-investor Evotec AG |
2016-03-22 |
| Topas Therapeutics–Gimv: investment, 201603 financing round Series A totalling €14m incl €4m from co-investor Gimv Health & Care |
2016-03-22 |
| Topas Therapeutics–SEVERAL: investment, 201603 financing round Series A €14m led by Epidarex incl EMBL Ventures + Gimv + Evotec |
2016-03-22 |
| GSK–Miltenyi Biotec: cell/gene therapy, 201603– collab cell + gene therapy incl CAR-T using increased automation |
2016-03-16 |
| SkyePharma–Vectura: investment, 201603– acquisition merger £441m in shares (up to £70m cash) resulting in 41.75% (37.62%) for former Skye owners |
2016-03-16 |
| Almirall–Grünenthal: investment, 201603– acquisition 100% of Almirall de Mexico SA de CV by Grünenthal ANNNOUNCED |
2016-03-15 |
| Bohui–Univ Freiburg: mass spec sample introduction technique, –201603 collab developm iASAP Prof Krossing + license of patent rights to Advion |
2016-03-15 |
| Roche–Blueprint Medicines: kinase inhibitors, 201603– collab ww $45m upfront + $965m milestones r+d + commerc up to 5 small molelcule drugs |
2016-03-15 |
| eTheRNA–Boehringer: investment, 201603 financing round Series A totalling €24m incl co-investor BIVF |
2016-03-14 |
| eTheRNA–Flanders (govt): investment, 201603 financing round Series A totalling €24m led by PMV + Life Sciences Partners |
2016-03-14 |
| eTheRNA–Fund+: investment, 201603 financing round Series A totalling €24m incl co-investor Fund+ |
2016-03-14 |
| eTheRNA–Life Sciences Partners: investment, 201603 financing round Series A totalling €24m led by Life Sciences Partners + PMV |
2016-03-14 |
| eTheRNA–Omega Funds: investment, 201603 financing round Series A totalling €24m incl co-investor Omega Funds |
2016-03-14 |
| eTheRNA–SEVERAL: investment, 201603 financing round Series A €24m led by Life Sciences Partners + PMV |
2016-03-14 |
| Agilent–Eurofins: genomic technology, 201603– collab Eurofins Genomics supplies custom components for Agilent’s SureVector cloning kits |
2016-03-10 |
| Aprea–MC Services: public relations, 201602 service existent for Aprea AB |
2016-03-09 |
| AbbVie–Boehringer: therap antibodies, 201603– collab + acqu ww rights BI 655066 + BI 655064 for $595m upfront + undisclosed milestones + royalties |
2016-03-07 |
| Argos–SEVERAL: investment, 201603– securities purchase agreem up to $60m common stock + warrants in 3 tranches incl Pharmstandard + TVM |
2016-03-07 |
| ITM Isotopen Technologien München–OTHER: investment, 201603 equity investment €20m from Medtech-focused family office |
2016-03-07 |
| Biocom–Nasdaq OMX: press release distribution, 201603 collab existent integration of channel news in Eurobiotechnews.eu portal |
2016-03-06 |
| Snowy Range Instruments–Metrohm: investment, 201603 acquisition of majority by Metrohm + SnRI renamed Metrohm Raman |
2016-03-04 |
| Biolink (NO)–Evonik: investment, 201603 acquisition €na of MedPalett AS by Evonik from Biolink Group |
2016-03-03 |
| Grünenthal–Axxam: drug discovery services, 201603– collab to discover small moleucule lead structures to treat pain + inflammation |
2016-03-03 |
| Pulsar Photonics–High-Tech Gründerfonds: investment, 201603 seed financing from HTGF |
2016-03-02 |
| Cycle GmbH–Hamburg (govt): investment, 201603 seed financing round incl HTGF + Innovationsstarter Hamburg + Tim Bode |
2016-03-01 |
| Cycle GmbH–High-Tech Gründerfonds: investment, 201603 seed financing round incl HTGF + Innovationsstarter Hamburg + Tim Bode |
2016-03-01 |
| Cycle GmbH–PERSON: investment, 201603 seed financing round incl HTGF + Innovationsstarter Hamburg + Tim Bode |
2016-03-01 |
| Cycle GmbH–SEVERAL: investment, 201603 seed financing round incl HTGF + Innovationsstarter Hamburg + Tim Bode |
2016-03-01 |
| Merck (DE)–EMBL: drug discovery, 201603–201902 collab research 3y with EMBL Heidelberg w focus on cancer metabolism |
2016-03-01 |
| Retina Implant–SEVERAL: investment, 201602 private equity funding round €26m from existing + new investors |
2016-02-29 |
| CPGR (ZA)–Thermo Fisher: mass spectrometer, 201602 supply existent Q Exactive MS system used for proteomics |
2016-02-26 |
| Blue Scientific–Accurion: laboratory instruments, 201602– distribution Nanofilm Technology + Halcyonics products in UK + Nordics by Blue Scientific |
2016-02-25 |
| Transcend Medical–Novartis: investment, 201602 acquisition €na by Alcon |
2016-02-18 |
| Saphetor–Capricorn One: public relations, 201602 service existent for Saphetor SA |
2016-02-17 |
| Saphetor–SEVERAL: investment, 201602 seed financing round CHF1.2m from undisclosed investors |
2016-02-17 |
| Venture Valuation–Nasdaq OMX: press release distribution, 201602– collab integration of channel news in Biotechgate online directories |
2016-02-17 |
| Apogenix–Germany (govt): grant, 201602 BMBF grant €3m for developm of companion diagnostic w R-Biopharm for APG101 in glioblastoma |
2016-02-16 |
| Novartis–Pfizer: biosimilar, 201602– Sandoz acquires rights to PF-06438179 (infliximab) in EEA which Pfizer had to divest after Hospira acquisition |
2016-02-12 |
| Curetis–Degroof Petercam: financial services, 201602– supply service liquidity provider to facilitate share trading on Euronext Brussels + Amsterdam |
2016-02-11 |
| Hemovent–SEVERAL: investment, 201602 financing round Series A $6m led by MIG Verwaltungs AG |
2016-02-10 |
| Qiagen–10x Genomics: genomic technology, 201602– collab co-developm + co-marketing of NGS + single-cell biology + bioinformatics solutions |
2016-02-09 |
| SmartDyeLivery–SEVERAL: investment, 201602 seed financing from bm|t + Sparkasse Jena-Saale-Holzland |
2016-02-03 |
| Evotec–Michael J Fox Foundation: grant, 201602 research grant for further developm of TargetaSN programme to treat Parkinson’s disease |
2016-02-02 |
| Mission Therapeutics–Roche: investment, 201602 financing round totalling £60m incl returning co-investor Roche Venture Fund |
2016-02-02 |
| PharmGenomics (DE)–SEVERAL: investment, 201601 financing round incl ISB + KfW + private investors |
2016-01-20 |
| Novartis–Surface Oncology: cancer immunotherapy, 201601– collab + license up to $170m in upfront + equity + milestones for 4 pre-clinical programs |
2016-01-11 |
| Novimmune–SEVERAL: investment, 201601 financing round CHF30m from existing shareholders |
2016-01-11 |
| Amgen–Biocartis: molecular companion diagnostics, 201712– collab €na developm liquid biopsy Idylla RAS CDx test for Vectibix |
2016-01-07 |
| C4 Therapeutics–Roche: investment, 201601 financing round Series A totalling $73m incl lead investor Cobro Ventures + co-investor Roche |
2016-01-07 |
| C4 Therapeutics–SEVERAL: investment, 201601 financing round Series A $73m led by Cobro plus Cormorant + Kraft Group + EG Capital + Roche + Novartis |
2016-01-07 |
| Roche–C4 Therapeutics: drug discovery, 201601– collab up to >750m developm TPD therapeutics against Roche targets using Degronimid platform |
2016-01-07 |
| Mecuris–Bavaria (govt): investment, 2016c seed financing round from Bayern Kapital + HTGF |
2016-01-01 |
| Mecuris–High-Tech Gründerfonds: investment, 2016c seed financing round from Bayern Kapital + HTGF |
2016-01-01 |
| Mecuris–SEVERAL: investment, 2016c seed financing round from Bayern Kapital + HTGF |
2016-01-01 |
| Merus–Minapharm: GlymaxX technology, 2016– non-excl license agreem for use of GlymaxX for Biclonics pipeline from ProBioGen AG |
2016-01-01 |
| MicrobeDx–Microfluidic ChipShop: microfluidics technology, 2016– collab developm + production of pharmacodiagnostic test systems |
2016-01-01 |
| Probiodrug–Crossbeta Biosciences: biomarker research, 2016– collab developm Alzheimer biomarker to support Probiodrug’s clinical AD program |
2016-01-01 |
| Storm Therapeutics–Evotec: drug discovery services, 2016– supply service HTS + structural biology to identify hits for 2 RNA modulating targets |
2016-01-01 |
| Mologen–Bâloise: investment, 201512 existing investor Bâloise Holding holding estimated 6% in Mologen |
2015-12-31 |
| Mologen–Deutsche Balaton: investment, 201512 existing investor holding estimated 5% in Mologen |
2015-12-31 |
| Mologen–Global Derivative Trading: investment, 201512 existing investor Global Derivative Trading GmbH owns estimated 24% in Mologen |
2015-12-31 |
| Mologen–Salvator Vermögensverwaltungs GmbH: investment, 201512 existing investor holding estimated 5% in Mologen |
2015-12-31 |
| Mologen–Signal Iduna: investment, 201512 existing investor Deutscher Ring Krankenversicherung holding estimated 6% in Mologen |
2015-12-31 |
| Boehringer–Polyphor: drug discovery, 201512 collab existent to identify + optimise drug candidates using macrocycle platform |
2015-12-22 |
| Complix–Selexis: biological contract manufacturing, 201512– supply SUREtechnology platform to enable production of Alphabody candidate CMX-02 |
2015-12-14 |
| NovaPump–SEVERAL: investment, 201512 financing round with bm|t + Sparkasse Jena-Saale-Holzland |
2015-12-14 |
| Basilea–SEVERAL: credit, 201512 senior unsecured convertible bonds CHF200m with coupon of 2.75% per annum due 2022 |
2015-12-09 |
| Convergence Pharmaceuticals–Evotec: investment, 201512 acquisition of 51% of shares of Panion Ltd |
2015-12-09 |
| Bridgepoint–Kohlberg Kravis Roberts: investment, 201512 acquisition €na of LGC by KKR from Bridgepoint |
2015-12-08 |
| Cypher Genomics–Human Longevity: investment, 201511 acquisition €na of Cypher Genomics by HLI |
2015-11-30 |
| TiGenix–Cormorant Asset Management: investment, 201511 private placement totalling €8.7m incl €4.7m to Cormorant Global Healthcare |
2015-11-25 |
| TiGenix–SEVERAL: investment, 201511 private placement €8.7m with 9.1m new shares €0.95/share to Cormorant + European institutional investors |
2015-11-25 |
| Merck (DE)–Univ Cape Town: malaria drug, 201511– collab research with UCT H3D to develop anti-malarial drug candidates using Merck compound library |
2015-11-19 |
| Greiner–Oncgnostics: cervical cancer test, 201511– distribution of GynTect test by Greiner Bio-One in DACH + FR + GB + Benelux |
2015-11-18 |
| Oncotest–Charles River: investment, 201511 acquisition of Oncotest GmbH for €34m in cash + €2m milestones |
2015-11-18 |
| Nestlé–ImaBiotech: mass spectrometry services, 201511– supply Multimaging services for Galderma’s drug development |
2015-11-10 |
| Syngenta–DSM: microbial agricultural solutions, 201511– collab developm microbial-based solutions incl bio-controls + bio-pesticides + bio-stimulants |
2015-11-06 |
| Omeicos–Germany (govt): grant, 201511– BMBF research grant €1.7m |
2015-11-02 |
| MTIP MedTech Innovation Partners–SEVERAL: investment, 201511–201604 1st closing CHF30m of 1st MTIP Fund |
2015-11-01 |
| Tusk Therapeutics–SEVERAL: investment, 201511 financing round Series A €30m |
2015-11-01 |
| Co.don–SEVERAL: investment, 201510–201511 capital increase €5m with 2.5m new shares at €2/share w existing + new investors |
2015-10-30 |
| GeneWake–R-Biopharm: investment, 201510 acquisition of GeneWake GmbH which had filed for bankruptcy in February 2015 |
2015-10-29 |
| Agena Bioscience–Diatech: mass spec-based MDx, 201510– collab developm MassARRAY genomic CDx tests for cancer therapy w Diatech Pharmacogenetics Srl |
2015-10-27 |
| Biofrontera–SEVERAL: investment, 201510–201511 capital increase €3.64m net €3.1m with 1.92m new shares at €2/share |
2015-10-27 |
| Arvinas–SEVERAL: investment, 201510 financing round Series B $41.6m led by RA Capital Management |
2015-10-21 |
| Science 37–Novartis: investment, 201510 financing round Series A totalling $6.5m co-led by Lux Capital + dRx Capital |
2015-10-20 |
| Science 37–SEVERAL: investment, 201510 financing round Series A $6.5m co-led by Lux Capital + dRx Capital |
2015-10-20 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 29 30 31 32 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
